Arrowhead Pharmaceuticals shares are moving higher on May 6, 2026 with a classic “ahead of earnings” setup: the company is scheduled to host its fiscal 2026 second-quarter results webcast and conference call on May 7, 2026 at 4:30 p.m. ET. With a biotech name that has a key commercial launch underway and multiple late-stage pipeline milestones, incremental buying into the print can be enough to push the stock several percent on no incremental same-day headline.

Beyond the calendar catalyst, sentiment has been supported by recent regulatory momentum for Redemplo (plozasiran). On April 23, 2026, the EMA’s CHMP adopted a positive opinion recommending marketing authorization for Redemplo for adults with familial chylomicronaemia syndrome (FCS), a step that often precedes a formal European Commission decision. That backdrop can lift expectations that Arrowhead’s first commercial product expands beyond the U.S. while the company continues to pursue larger hypertriglyceridemia opportunities.

On the May 7 call, investors typically focus on (1) early launch indicators for Redemplo (patient starts, payer coverage, and commercial infrastructure buildout), (2) updated timelines for plozasiran’s broader Phase 3 program and any planned supplemental filing strategy, and (3) cash runway and spending cadence. Any new color on 2026 catalysts and commercialization execution could be the difference between a “sell-the-news” reaction and a follow-through move.